Pat Latterell
InvestorFounder at Latterell Venture Partners
About
Pat Latterell founded Latterell Venture Partners (LVP) in 2001 after spending 14 years as a General Partner at Venrock Associates. He previously was a General Partner at Rothschild Ventures and an executive at Syntex Pharmaceuticals, where he helped set up its venture capital program, and earlier conducted molecular biology and biomedical engineering research at MIT. His career has focused on startup and early-stage healthcare investments, contributing to the formation of more than three dozen medical companies. He holds an MBA from Stanford Business School and SB degrees in biological sciences and economics from MIT.
Contact· self-published, not guessed
Invests in
BiotechHealthtechMedical Devices
Investments
Investor
Cardiothoracic SystemsEnsure MedicalEP TechnologiesGeronIntegrated Vascular SystemsIsis PharmaceuticalsMicrogenicsOmniflowOncomed PharmaceuticalsOratec InterventionsPerseptive BiosystemsPharmacyclicsProteolixSepracorSignal PharmaceuticalsVical
Per the firm's website.
Colleagues at Latterell Venture Partners
Frequently asked questions
- Who is Pat Latterell?
- Pat Latterell founded Latterell Venture Partners (LVP) in 2001 after spending 14 years as a General Partner at Venrock Associates. He previously was a General Partner at Rothschild Ventures and an executive at Syntex Pharmaceuticals, where he helped set up its venture capital program, and earlier conducted molecular biology and biomedical engineering research at MIT. His career has focused on startup and early-stage healthcare investments, contributing to the formation of more than three dozen medical companies. He holds an MBA from Stanford Business School and SB degrees in biological sciences and economics from MIT.
- Where does Pat Latterell work?
- Pat Latterell is Founder at Latterell Venture Partners.
- What does Pat Latterell invest in?
- Pat Latterell invests in Biotech, Healthtech, Medical Devices.
- What companies has Pat Latterell invested in?
- Investments tracked here include Cardiothoracic Systems, Ensure Medical, EP Technologies, Geron, Integrated Vascular Systems, Isis Pharmaceuticals, Microgenics, Omniflow, Oncomed Pharmaceuticals, Oratec Interventions, Perseptive Biosystems, Pharmacyclics, and 4 more.